Evidence map›Paper›PMID 28333957›Full record

ArticlePLoS neglected tropical diseases2017

Immune response of rats vaccinated orally with various plant-expressed recombinant cysteine proteinase constructs when challenged with Fasciola hepatica metacercariae.

Malgorzata Kesik-Brodacka, Agnieszka Lipiec, Monika Kozak Ljunggren, Luiza Jedlina, Katarzyna Miedzinska, Magdalena Mikolajczak, Andrzej Plucienniczak, Andrzej B Legocki, Halina Wedrychowicz

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Edible Vaccines: Promises and Challenges.Molecular biotechnology · 2020
    Review
  5. Progress in biopharmaceutical development.Biotechnology and applied biochemistry · 2018
    Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Malgorzata Kesik-BrodackaDepartment of Bioengineering, Institute of Biotechnology and Antibiotics, Warsaw, Poland.ORCID 0000-0003-1363-7986
Agnieszka LipiecDivision of Parasitology, Faculty of Veterinary Medicine, Warsaw University of Life Sciences, Warsaw, Poland.
Monika Kozak LjunggrenWitold Stefański Institute of Parasitology, Polish Academy of Sciences, Warsaw, Poland.
Luiza JedlinaWitold Stefański Institute of Parasitology, Polish Academy of Sciences, Warsaw, Poland.
Katarzyna MiedzinskaInstitute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland.
Magdalena MikolajczakInstitute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland.
Andrzej PlucienniczakDepartment of Bioengineering, Institute of Biotechnology and Antibiotics, Warsaw, Poland.
Andrzej B LegockiInstitute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland.
Halina WedrychowiczWitold Stefański Institute of Parasitology, Polish Academy of Sciences, Warsaw, Poland.
Institute of Bioorganic Chemistry, Polish Academy of Sciences · PLWitold Stefański Institute of Parasitology · PLInstytut Biotechnologii i Antybiotyków · PLWarsaw University of Life Sciences · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCysteine proteinases of Fasciola hepatica are important candidates for vaccine antigens because of their role in fluke biology and host-parasite relationships. In our previous experiments, we found that a recombinant cysteine proteinase cloned from adult F. hepatica (CPFhW) can protect rats against liver fluke infections when it is administered intramuscularly or intranasally in the form of cDNA. We also observed considerable protection upon challenge following mucosal vaccination with inclusion bodies containing recombinant CPFhW produced in Escherichia coli. In this study, we explore oral vaccination, which may be the desired method of delivery and is potentially capable of preventing infections at the site of helminth entry. To provide antigen encapsulation and to protect the vaccine antigen from degradation in the intestinal tract, transgenic plant-based systems are used. METHODOLOGY: In the present study, we aimed to evaluate the protective ability of mucosal vaccinations of 12-week-old rats with CPFhW produced in a transgenic-plant-based system. To avoid inducing tolerance and to maximise the immune response induced by oral immunisation, we used the hepatitis B virus (HBV) core protein (HBcAg) as a carrier. Animals were immunised with two doses of the antigen and challenged with 25 or 30 metacercariae of F. hepatica.

conclusionsWe obtained substantial protection after oral administration of the plant-produced hybrids of CPFhW and HBcAg. The highest level of protection (65.4%) was observed in animals immunised with transgenic plants expressing the mature CPFhW enzyme flanked by Gly-rich linkers and inserted into c/e1 epitope of truncated HBcAg. The immunised rats showed clear IgG1 and IgM responses to CPFhW for 4 consecutive weeks after the challenge.

Indexed as

Administration, OralAnimalsAntibodies, HelminthAntigens, HelminthCysteine ProteasesDNA, ComplementaryFasciola hepaticaFascioliasisHost-Parasite InteractionsImmunoglobulin GImmunoglobulin MMaleMetacercariaePlants, Genetically ModifiedRandom AllocationRatsAntibodies, HelminthAntigens, HelminthCysteine ProteasesDNA, ComplementaryImmunoglobulin GImmunoglobulin MRecombinant ProteinsVaccines, DNA

Identifiers

PMID28333957
PMCPMC5383346
OpenAlexW2601680518

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.